Search Femetric

Search peptides, goals, protocols and references

RESEARCH REVIEW

Glutathione and Skin Pigmentation

What human trials show

REVIEWED 2026-09-12UPDATED 2026-09-127 MIN READHuman clinical literature indexed by Femetric through September 2026
01

Executive snapshot

Research contextSmall human trialsNo evidence score
Route studiedOral formulationsRoute-specific
Primary signalPigmentation outcomes reportedLimited study base
Main limitationSmall samples and heterogeneous measuresLong-term relevance uncertain
02

Research question

What do controlled human studies actually show about glutathione and skin pigmentation, and how much can be generalized across formulations and routes?

03

Mechanism

Glutathione participates in cellular redox chemistry and has been studied in relation to melanogenesis pathways.

Mechanistic plausibility does not make oral, topical and parenteral formulations interchangeable. This review keeps route and formulation attached to each source.

04

Evidence in the indexed literature

Randomized, double-blind, placebo-controlled pigmentation study60 randomized participants
Population
Healthy medical students
Protocol
Oral glutathione or placebo
Duration
4 weeks
Primary outcome
Melanin index at measured sites
Result
The publication reported lower melanin indices at some measured sites; findings were not uniform across every site.
Women included
Mixed-sex enrollment; Femetric has not yet extracted a verified female count.
Randomized controlled trial of oral glutathione on body stores54 adults
Population
Healthy adults
Protocol
Oral glutathione at two dose levels or placebo
Duration
6 months
Primary outcome
Glutathione concentrations in blood compartments and cells
Result
This study addressed systemic glutathione status rather than pigmentation efficacy and provides route/context support only.
Women included
Mixed-sex enrollment; sex-specific outcomes were not indexed by Femetric.
05

Women in the research

participation

Women were included in the indexed human literature, but a verified female-participant count has not been extracted for every paper.

sex Outcomes

Femetric has not identified a source-supported sex-stratified pigmentation result in the indexed studies.

dose Structure

No female-specific dose structure is represented.

life Stage

No female life-stage protocol is established by these records.

limitations

Representation and sex-specific reporting are different questions; inclusion alone does not establish female-specific outcomes.

06

What the research currently supports

STRONGEST CONCLUSION

Small controlled human studies provide a research signal worth indexing, but the evidence is not broad enough to treat formulation, route, dose and outcome as interchangeable.

WHAT REMAINS UNCERTAIN

Durability, clinical significance, formulation comparability and long-term outcomes remain uncertain in the indexed source set.

WHAT WE’RE WATCHING

Larger preregistered trials with standardized pigmentation measures and transparent sex-specific reporting.

07

Key studies + full references

NEXT RESEARCH ACTION
Was this useful?